Natco Pharma has concludes Qualified Institutional Placement (QIP) issue by completing the allocation of 3 million shares of Rs 10 face value at Rs 225 to seven institutional investors. Pursuant to this, the company has been able to raise Rs 67.50 crore and it plans to use the proceeds to fund its expansion plans. The promoter stake in the company has come down to around 58% from 61% earlier.
Further, Kotak India Venture Fund-I has acquired a 3.4% stake, around 1.05 million shares through the issue by investing Rs 23.7 crore. Also, Orange Mauritius Investments which already holds 2.72% stake in the company, has raised its stake close to 6% post QIP.
Natco Pharma manufactures a comprehensive range of branded and generic dosage forms, bulk actives and intermediates for both Indian as well as International markets. Company’s product range includes Diltiazem, Omeprazole, Lansoprazole, Isosorbides, Sumatriptan, succinate, Ondansetron, Sertraline, Granisetron, Paroxetine , Newer Quinolones and fourth genaration Cephalosorins.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1779.35 |
| Dr. Reddys Lab | 1267.05 |
| Cipla | 1397.75 |
| Zydus Lifesciences | 1085.45 |
| Lupin | 2248.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: